🔗 Share this article

While America undertakes unprecedented changes to its vaccination recommendations, one figure has emerged somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on Covid vaccinations during the pandemic and has concentrated on alleged deaths following Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Health officials were set to unveil sweeping revisions to the pediatric vaccine schedule in December, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would place the US at odds with much of the global community with insufficient data for public health gain. The announcement has been pushed back until the new year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

Consolidating Power at the Regulatory Body

This interim role could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing certain childhood vaccine recommendations in the US in order to be more like Denmark, a country with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no apparent track record in medication creation, oversight or leadership, which has been customary for former directors of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “be deeply familiar with legal statutes and the science of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who headed the center have had.”

The drug center has an immense portfolio at the agency, she pointed out.

“The public just pays attention on the innovative therapies, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one must be supervised,” Woodcock noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a major administrative aspect to the position, which manages more than 5,000 personnel. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Programs

In response to concerns about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among agency officials on vaccines, a spokesperson stated that the “questions are based on flawed assumptions”.

“Her resume aligns with the functions of her role,” the spokesperson said, pointing to the time Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s controversial priority voucher program, a disputed expedited medication authorization process that allegedly worried her former heads. “By what process are these drugs being selected for this voucher program? Who is making the decisions?” Dr. Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he said, “the agency looks to be trending towards less stringent regulations of pharmaceuticals, aside from vaccines.”

Public Track Record on Immunizations

Regarding vaccines, Høeg has a more documented, if troubling, history, critics said. She released a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership included revising regulations for new vaccines and halting “optional” immunizations, she said post-election on a podcast. At the FDA, Høeg has reportedly proposed barring adolescent males from getting COVID-19 vaccines.

“She is an all-around true believer who commences with her beliefs and tailors the evidence to fit the science in a very disingenuous, dishonest way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|